A new collaboration between TNO, Proefdiervrij, and pharmaceutical company Galapagos, called MechPath, is accelerating the transition to animal-free drug development. By combining patient data, lab-based human cell models, and artificial intelligence, the MECHanistic PATHology (MechPath) approach allows researchers to identify patterns and make reliable predictions without relying on animal testing.
Key results so far:
Human cells used in lab models appear to retain a “disease memory,” continuing to respond as if they were still in the body, offering more realistic models for conditions like fibrosis.
The newly developed CELLS-PATH validation tools help lab-grown models gain approval faster, paving the way for wider adoption in drug research.
Leiden Bio Science Park welcomes Eli Lilly, strengthening The Netherlands' position in life sciences with a $3 billion facility. Eli Lilly and Company announced plans to build a...
From the Van Nelle Factory to BioPartner 5, from heritage to future, from start-up to innovative lab design agency. After an inspiring and innovative seven-year start at the...
Starting Friday, November 14 at 4:00 p.m., two temporary closures (in place for the duration of the Plesmanlaan project, until approximately Q3 2027) will be implemented for...